In Brief: Boston Scientific's NIR ON Ranger
This article was originally published in The Gray Sheet
Boston Scientific's NIR ON Ranger: Premarket approval application for the company's NIR coronary stent mounted on an over-the-wire catheter is submitted to FDA. Data from the NIRVANA stent trial, which was conducted by Boston Scientific's Medinol division, were submitted in support of the PMA. Boston Scientific also completes enrollment for a separate patient registry related to a NIR ON Ranger rapid-exchange delivery system that the company claims does not infringe patents held by competitors Guidant and Pfizer's Schneider unit. Results of the registry will be submitted as a PMA supplement, the company says...
You may also be interested in...
With Brexit less than a month old, Germany’s medtech industry has renewed its push for an MRA between the EU and UK in medtech regulation.
Days after a senior Chinese government official offered free COVID-19 vaccines to the Philippines government, the country’s medicines regulator said the donated jabs would need an emergency approval before they can be used on the public.
Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.